HYPERTENSION IN PATIENTS TREATED WITH IBRUTINIB FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
Author(s): ,
Lindsey Roeker
Affiliations:
Memorial Sloan Kettering Cancer Center,New York,United States
,
Maryam Yazdy
Affiliations:
Georgetown University Hospital Lombardi Comprehensive Cancer Center,Washington,United States
,
Lisa Gashonia
Affiliations:
University of Pennsylvania,Philadelphia,United States
,
Julie Goodfriend
Affiliations:
Memorial Sloan Kettering Cancer Center,New York,United States
,
Mayur Narkhede
Affiliations:
Georgetown University Hospital Lombardi Comprehensive Cancer Center,Washington,United States
,
Joanna Rhodes
Affiliations:
Abramson Cancer Center, University of Pennsylvania,Philadelphia,United States
,
Kaitlin Kennard
Affiliations:
Abramson Cancer Center, University of Pennsylvania,Philadelphia,United States
,
Hannah Morse
Affiliations:
Memorial Sloan Kettering Cancer Center,New York,United States
,
Colleen Dorsey
Affiliations:
Memorial Sloan Kettering Cancer Center,New York,United States
,
Kristen Battiato
Affiliations:
Memorial Sloan Kettering Cancer Center,New York,United States
,
Marissa Peterson
Affiliations:
Memorial Sloan Kettering Cancer Center,New York,United States
,
Joseph Carver
Affiliations:
University of Pennsylvania,Philadelphia,United States
,
Stephen Schuster
Affiliations:
Abramson Cancer Center, University of Pennsylvania,Philadelphia,United States
,
Bruce Cheson
Affiliations:
Georgetown University Hospital Lombardi Comprehensive Cancer Center,Washington,United States
Anthony Mato
Affiliations:
Memorial Sloan Kettering Cancer Center,New York,United States
EHA Library. Roeker L. Jun 14, 2019; 266186; PF386
Dr. Lindsey Roeker
Dr. Lindsey Roeker
Contributions
Abstract

Abstract: PF386

Type: Poster Presentation

Presentation during EHA24: On Friday, June 14, 2019 from 17:30 - 19:00

Location: Poster area

Background
Hypertension (HTN) is the most common grade ≥ 3 Ibrutinib (Ibr)-associated adverse event (AE) observed in clinical trials (26%) (O’Brien, Blood 2015). Meta-analysis of clinical trial data suggests a 2.8-fold increased risk of HTN for patients (pts) treated with Ibr vs. placebo (Caldeira, PLOS ONE 2019). In clinical practice, data regarding incidence, medication management, and long term vascular consequences of Ibr-associated HTN are limited. As Ibr is administered in a continuous fashion and HTN incidence is cumulative, this toxicity is presently understudied.

Aims
To describe the incidence of HTN, as well as baseline comorbidities, change in blood pressure (BP) over time, and changes in cardiovascular (CV) medications for CLL pts treated with Ibr in routine clinical practice.

Methods
Multicenter, retrospective cohort study of CLL pts treated with 420 mg Ibr for at least 6 months. We collected baseline CV comorbidities, baseline CV medications, BP measurements prior to Ibr initiation and sequentially following exposure at specific time points over a 12-month period, and adjustments to CV medications in response to Ibr-associated HTN (up or 1 year). Incident HTN is defined as BP > 140/90 mmHg, and worsening BP control is defined as sustained rise in SBP or DBP ≥ 3 mmHg over baseline.

Results
We identified 247 Ibr treated CLL pts. Pre-Ibr CV comorbidities included: HTN (43%), hyperlipidemia (35%), diabetes (16%), coronary artery disease (CAD; 9.7%), heart failure (2.0%), valvular heart disease (2.8%), atrial fibrillation (Afib; 4.5%), other arrhythmia (6.5%), stroke (2.8%), and smoking history (42%). At least one anti-HTN medication was used in 51% prior to Ibr initiation (median number of meds 1, range 0-6, 33% ≥ 2 meds). Median BP prior to Ibr exposure was 127/71 mmHg (range 92-174/48-95) and median pulse 75 bpm (range 27-110). Median peak BP following Ibr exposure was significantly elevated (153/80 mmHg range 105-218/53-121, p<0.0001). Median time to peak BP was 6 months (range 0-35 months). Figure 1 depicts median systolic BP at baseline and 1, 3, 6, 9, and 12 months following Ibr initiation. During the observation period, 36% and 84% experienced new HTN or worsening of existing HTN respectively. 19.8% of pts required initiation of at least one new anti-HTN medication, and 4.7% required increased dose of a pre-Ibr anti-HTN medication. Of the 49 pts who required BP management, 86% started 1 new agent, and 14% started ≥2 new agents. The most common new classes of agents selected were beta blockers (32%), angiotensin receptor blockers (21%), diuretics (19%), calcium channel blockers (14%), and angiotensin converting enzyme inhibitors (14%). Regarding CV events following Ibr initiation, 6.4% experienced new onset Afib, 1.6% had CAD. Preexisting CV comorbidities, smoking history, and diabetes were not predictive of HTN development in univariate analysis.

Conclusion
HTN is a pervasive AE of Ibr affecting pts with and without baseline HTN or CV conditions. Physiologically, systolic blood pressure appears to be more significantly affected than diastolic blood pressure. While these data demonstrate 20% of pts adjust current anti-HTN meds or start new ones, it is not known how effective current management is at controlling this AE or preventing long term vascular events. In addition, we demonstrate that the proportion of pts initiating new anti-HTN meds appears to be significantly lower than those experiencing new/worsening HTN, identifying a potential opportunity for care optimization in partnership with cardio-oncology.

Session topic: 6. Chronic lymphocytic leukemia and related disorders - Clinical

Keyword(s): Chronic lymphocytic leukemia, Clinical data, Ibrutinib, Toxicity

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies